A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine.
Region II of the erythrocyte-binding antigen (EBA-175 RII) has been identified as a promising target for a malaria vaccine. A systematic approach to identify optimal preformulation conditions of a non-glycosylated (NG) antigen, EBA-175 RII-NG, has been developed. This approach consists of development of an empirical temperature/pH phase diagram, high throughput stabilizer screening and aluminum salt adjuvant adsorption studies. Using these physical methods, we developed a stable formulation for EBA-175 RII-NG at pH 6.0 with sucrose and Brij 35 as stabilizers and Adju-Phos as an adjuvant. This approach should be generally applicable to guiding the development of stable vaccine formulations.
Peek
Laura J
LJ
Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, KS 66047, USA.
Brandau
Duane T
DT
Jones
LaToya S
LS
Joshi
Sangeeta B
SB
Middaugh
C Russell
CR
D000818:Animals; D000953:Antigens, Protozoan; D002626:Chemistry, Pharmaceutical; D004355:Drug Stability; D017780:Malaria Vaccines / Q000138:chemical synthesis* / Q000592:standards; D010963:Plasmodium falciparum; D015800:Protozoan Proteins / Q000138:chemical synthesis* / Q000592:standards
D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D015800:Protozoan Proteins; C065668:erythrocyte-binding antigen 175, Plasmodium